Evidence map›Paper›PMID 25663954›Full record

ArticleJournal of cancer research updates2014

lincRNA HOTAIR as a novel promoter of cancer progression.

Gregory Loewen, Ying Zhuo, Yan Zhuang, Janarthanan Jayawickramarajah, Bin Shan

Abstract read
In one paragraph

Article in Journal of cancer research updates, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Cell cycle (Georgetown, Tex.) · 2020
    Article
  5. Article
  6. Genetic Variants ofFrontiers in oncology · 2020
    Article
  7. Review
  8. Genomics & informatics · 2017
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Functions of lncRNA HOTAIR in lung cancer.Journal of hematology & oncology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gregory LoewenProvidence Regional Cancer Center, 105 W. 8th Avenue, Spokane, WA 99204 USA.
Ying ZhuoMedical Oncology Associates, 6001 North Mayfair Street, Spokane, WA 99208 USA.
Yan ZhuangDepartment of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA.
Janarthanan JayawickramarajahDepartment of Chemistry, Tulane University, 2015 Percival Stern Hall, New Orleans, LA 70118 USA.
Bin ShanCollege of Medical Sciences, Washington State University Spokane, 412 E. Spokane Falls Boulevard, Spokane, WA 99202 USA.

Funding

Supramolecular Approaches to Protein Inhibitors Activated by MicroRNA-21R01GM097571 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI JAYAWICKRAMARAJAH, JANARTHANAN · 2012 to 2016
$1.4M
NIGMS NIH HHS R01 GM097571
6 · The paper itself

Abstract

Large intergenic non-coding RNAs (lincRNA) regulate development and disease

Indexed as

cancerEZH2lincRNAmetastasisPRC2

Identifiers

PMID25663954
PMCPMC4318250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.